COVID-19 Antigens

  • Use Sengenics’ correctly folded spike, nucleocapsid or envelope COVID-19 antigens for production of a high-affinity vaccine

  • Development of an antigen-based COVID-19 sero-diagnostic test for patient screening or immunosurveillance purposes

  • Fundamental research: characterisation of full-length, correctly folded and functional SARS-CoV-2 antigens

ImmuSAFE COVID+ Biochip Test

  • World’s first high-throughput, multi-domain COVID-19 antibody test

  • Population antibody profiling for seroprevalence research

  • Determine the protective quality and quantity of antibodies produced

  • Enable quantitative assessment of antigen-specific response by individuals in vaccine trials

IMMUNOME Market Array

  • High-throughput platform for autoantibody biomarker discovery and protein-protein interactions
  • Exploratory arrays capable of screening over 1600 proteins in quadruplicate
  • Picogram level sensitivity – fully quantitative assay
  • Exceptional consistency and batch-to-batch reproducibility

CTA Array

  • High-throughput quantification of autoantibodies to Cancer-Testis (CT) antigens
  • Patient stratification in checkpoint inhibitor studies
  • Picogram level sensitivity – fully quantitative assay
  • Exceptional consistency and batch-to-batch reproducibility

Custom Arrays

  • Parallel screening of multiple samples on one slide
  • Proteins can be selected from our existing library or can be custom made
  • Choose from 2, 4, 8 or 16-plex format
  • Bespoke content and project design service

OncoREX p53 Cancer Array

  • Cancer drug screening and discovery
  • Screen 100 mutant p53 protein array in one experiment
  • Same chip can also be used for aAb specificity and analysis
  • Protein spotted in triplicate


Resources to access our technology


Your technical questions - answered


One technology - endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics UK Ltd. Registered in England and Wales no. 12889389 | Sengenics Corporation Pte. Ltd. Registered in Singapore no. 201734100D